Zealand Pharma A/S

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2026-02-13 EST			5-day change	1st Jan Change
399.70 ^DKK	-2.20%		-1.87%	-14.30%

02-13	Diary - Europe's STOXX 600 Corporate Earnings Week Ahead	RE
02-09	DNB Carnegie Lowers Price Target for Zealand Pharma to 595 Danish Kroner (610), Reiterates Buy	FW

Zealand Pharma A/S(CPSE:ZEAL) added to OMX Nordic 40 Index

Published on 12/22/2024

S&P Capital IQ

ZEALAND PHARMA A/S

-2.20%

OMX STOCKHOLM 30 INDEX

-0.12%

OMX NORDIC 40

-0.22%

Zealand Pharma A/S Added to OMX Nordic 40 Index.

Stocks mentioned in the article

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
ZEALAND PHARMA A/S	399.70DKK	-2.20%	-1.87%	4.47B
OMX STOCKHOLM 30 INDEX	3,119.76PTS	-0.12%	-0.02%	-
OMX NORDIC 40	2,643.50PTS	-0.22%	+0.11%	-

Latest news about Zealand Pharma A/S

02-13	Diary - Europe's STOXX 600 Corporate Earnings Week Ahead	RE
02-09	DNB Carnegie Lowers Price Target for Zealand Pharma to 595 Danish Kroner (610), Reiterates Buy	FW
02-04	U.S. Futures, European Stocks Rise	DJ
01-30	AstraZeneca Strikes Obesity Multibillion-Dollar Deal With China's CSPC Pharmaceuticals -- Update	DJ
01-27	Roche Obesity Shot Helps Patients Lose Weight in Midstage Trial -- Update	DJ
01-16	SEB Lists Nordic Favorites for Q1, Highlights a Swedish Quartet of Smaller Companies as Most Interesting	FW
01-14	Zealand Pharma A/S Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 01:30 PM
01-09	Zealand Pharma to Boost Drug Discovery via Denmark Supercomputer	MT
01-09	Zealand Pharma to use Gefion AI to accelerate drug discovery	RE
12-31	U.S. Futures Fall, European Stocks Mostly Lower	DJ
12-29	Insight: Pills, TikTok and weight-loss apps: the consumer-driven future of GLP-1s	RE
12-23	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
12-16	Deutsche Bank raises its target price for Zealand Pharma to DKK 450 (430), reiterates hold	FW
12-15	Zealand Pharma A/S - Analyst/Investor Day
12-12	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE

Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2024, the Group had a portfolio of 6 products in clinical development (including 3 in phase III, 2 in phase II and 1 in phase I), and 2 products in preclinical development.

Employees

440

Sector

Biotechnology & Medical Research

Calendar

02-19 - Q4 2025 Earnings Release

More about the company